NEW YORK, March 16, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of HeartWare International, Inc. (“HeartWare”) (NASDAQ:HTWR) between June 10, 2014 and January 11, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired HeartWare securities between June 10, 2014 and January 11, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/heartware.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/heartware.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
John Ternus Signals Apple’s Future with Product-First AI Strategy 



